New FOURIER Analysis Shows Repatha ® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Data Supports Safety and Efficacy of Repatha in Patients With Diabetes Simultaneously Presented at EASD 2017 and Published in The Lancet Diabetes & Endocrinology THOUSAND OAKS, Calif., Sept. 15, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a new analysis of the cardiovascular outcomes study (FOURIER) demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha® (evolocumab) significantly and consistently reduced cardiovascular events in patients with and without diabetes at baseline. The analysis showed that diabetes was independently associated with a substantially increased risk of cardiovascular morbidity and mortality in patie...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news